Home › Burkitt Lymphoma › Massachusetts › Boston

Pag-aaral pangklinika para sa Burkitt Lymphoma sa Boston, MA

Isang pag-aaral para sa Burkitt Lymphoma ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Boston. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.

Opisyal na teksto ng pag-aaral (English)

Nagha-hire para sa pag-aaral dito? I-highlight ito sa tuktok ng pahinang ito — $99 sa loob ng 30 araw →

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Nagre-recruitPhase 2

Dana-Farber Cancer Institute, Boston

366 Days – 46 Years · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT06124157

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Nagre-recruitPhase 3

Dana-Farber Cancer Institute, Boston

Edad 18 hanggang 39 · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT03150693

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Nagre-recruitPhase 2

Dana-Farber Cancer Institute, Boston

365 Days · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06317662

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

Nagre-recruitPhase 1/2

Dana-Farber Cancer Institute ( Site 1013), Boston

6 Months – 25 Years · Lahat ng kasarian · Na-update Set 17, 2026 · NCT06395103

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

Nagre-recruitPhase 1

Tufts Medical Center, Boston

Edad 18 pataas · Lahat ng kasarian · Na-update Set 8, 2026 · NCT03666000

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Nagre-recruitPhase 3

Massachusetts General Hospital Cancer Center, Boston
Dana-Farber Cancer Institute, Boston

365 Days – 25 Years · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT03959085

Study of SGR-1505 in Mature B-Cell Neoplasms

Nagre-recruitPhase 1

Beth Israel Deaconess Medical Center, Boston

Edad 18 pataas · Lahat ng kasarian · Na-update Peb 13, 2026 · NCT05544019

ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

Nagre-recruitPhase 1

Dana Farber Cancer Institute, Boston
Beth Israel Deaconess Medical Center, Boston

Edad 18 pataas · Lahat ng kasarian · Na-update Nob 4, 2025 · NCT03595917

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

Nagre-recruitPhase 1/2

Dana Farber Cancer Institute, Boston

Edad 15 hanggang 50 · Lahat ng kasarian · Na-update Set 9, 2025 · NCT04150497

The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL

Nagre-recruitPhase 2

Floating Hospital for Children at Tufts Medical Center, Boston
Dana Faber Cancer Institute/ Boston Children's Hospital, Boston

Edad 1 hanggang 25 · Lahat ng kasarian · Na-update May 4, 2025 · NCT03509961

Pag-aaral para sa Burkitt Lymphoma sa ibang lungsod

Iba pang pag-aaral sa Boston

Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.